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1. Introduction 
Chronic hyperglycemia associated with type 2 diabetes mellitus (T2D) is a result of deficient 
insulin secretion and/or resistance of target tissues to insulin’s action. Chronic 
hyperglycemia is a major etiological factor causing both micro- and macrovascular lesions 
associated with diabetes. Numerous biochemical changes initiated by hyperglycemia 
directly influence cellular function and lead to abnormal vascular remodeling and the 
development of vascular diabetic complications (Wadham et al., 2007, King et al, 1996, 
Brownlee, 2001). 
Recent literature data states that the innate immune system might be involved in the 
pathogenesis of type 2 diabetes. It is now commonly accepted that diabetes is associated 
with low-grade inflammation; there are a lot of human studies that demonstrate an increase 
for some of the inflammatory markers (hsCRP) including interleukins (IL-6, etc) and several 
adhesion molecules (intercellular adhesion molecule 1, ICAM-1, E-selectin) in patients with 
T2D, compared to controls (Garcia et al, 2010). Type 2 diabetes is initiated as a result of both 
genetic and acquired individual factors associated with triggering stimuli such as 
overeating, under-activity, increasing age, psychological stress and smoking. All these are 
also responsible for the activation of innate immunity, leading to insulin resistance (Garcia 
et al, 2010). 
Obesity induces changes in skeletal muscle, adipose tissue and the liver that result in 
localized inflammation and insulin resistance (IR) through autocrine and paracrine 
signaling. Excess adiposity is the most important risk factor for the development of insulin 
resistance, type 2 diabetes and their cardiovascular complications (Tataranni, 2005). Insulin 
resistance is extensively studied by medical and scientific communities because of its 
increased prevalence and its association with cardiovascular disease. Even if the precise 
molecular mechanism(s) linking insulin resistance to the development and/or progression 
of atherosclerosis remains under debate, it is clear that inflammation is a contributing factor. 
The exact physiological events leading to the initiation of the inflammatory response in 
obesity remain incompletely understood. Adipokines such as resistin and leptin, which are 
secreted by adipocytes, can induce inflammation and the associated insulin resistance. As 
part of the chronic inflammatory process, chemokines secreted locally, in the adipose tissue, 
attract pro-inflammatory macrophages that contribute to the acceleration of inflammatory 
markers’ synthesis (Zavaroni I, 2000, De Luca 2008).  
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Adiponectin is one of the adipocyte-derived proteins that have insulin-sensitizing, 
antiinflammatory, and antiatherogenic properties. Clinical studies show that decreased 
plasma levels of adiponectin have been associated with obesity, type 2 diabetes, and 
hypertension; plasma adiponectin levels are significantly lower in patients with coronary 
artery disease. Experimental as well as clinical studies strongly suggest that physiologic 
levels of adiponectin are necessary to maintain the normal, non-inflammatory phenotype of 
the vascular wall and that the protective role of adiponectin is due to it’s capacity to 
preserve the endothelial cell function (Ouedraogo et al, 2007,  Goldstein & Scalia, 2004, 
Scherer, 2006, Arita et al, 1999, Hotta et al, 2000, Iwashima et al, 2004, Ouchi et al, 2000).  
Relative risk of cardiovascular disease is increased 2–3 times in diabetic men and 3–4 times 
in diabetic women compared to non-diabetic controls; atherosclerosis is the major causal 
factor for these pathological events (Ray et al, 2009). Blood-borne inflammatory and immune 
cells constitute an important part of the atheroma lesions; activated immune cells in the 
atherosclerotic plaque produce inflammatory cytokines (interferon, interleukin-1, and 
tumor necrosis factor), which induce the production of substantial amounts of interleukin-6 
(IL6) and other inflammatory factors (Hansson, 2005). Therefore inflammation is an 
important component in the development of atherosclerosis specifically in the setting of 
type 2 diabetes and insulin resistance. 
In patients at high risk of cardio-vascular disease, the first signs of endothelial dysfunction 
are observed in morphologically intact vessels, before the onset of clinically manifested 
vascular disease. There are several lines of evidence indicating especially that endothelial 
function is compromised in situations associated with reduced sensitivity to endogenous 
insulin. The adhesion of circulating leukocytes to endothelial cells plays an important role in 
the initiation of atherosclerosis. Cellular adhesion molecules are poorly expressed by the 
resting endothelium, but they are up-regulated during atherogenesis;  the soluble forms of 
some cellular adhesion molecules, such as E-selectin, can be found in plasma and it has been 
suggested that elevated plasma levels of these cellular adhesion molecules may constitute  
an index of endothelial activation or even a molecular marker of early atherosclerosis 
(Ceriello, 2004, Stühlinger, 2002). Adhesion molecules (E-selectin, ICAM1, VCAM) as well as 
cytokines are up-regulated under the effect of hyperglycemia (Zheng et al, 2007, Miyamoto 
et al, 1999, Joussen et al, 2002). 
Nitric-oxide (NO) is synthesized from L-arginine by a family of enzymes, called NO 
synthases (NOSs) and has antiatherogenic and antithrombotic functions. The constitutively 
expressed NOS isoforms, endothelial NOS (eNOS) and neuronal NOS (nNOS), are likely to 
be the major contributors to whole-body NO production. In the last decades, a great effort 
has been made to understand the role of NO as a modulator of physiological insulin 
secretion as well as its ability to modulate glucose metabolism and its’ involvement in 
insulin resistance. It has been described that eNOS activation, specifically localized in 
skeletal muscles, increases muscle blood flow, with increased delivery of glucose to the 
muscle cell (Monti L.D., 2003). In endothelial cells, insulin stimulates the expression and 
activity of endothelial NO synthase (eNOS), resulting in increased production of NO. Under 
normal circumstances, NO is not only critically important in the process of vasodilatation, 
but it also counteracts the stimulatory effect of VEGF on the expression of adhesion 
molecules such as E-selectin, intracellular adhesion molecule (ICAM1), and vascular cellular 
adhesion molecule (VCAM), thereby protecting the endothelial cells from excessive 
interactions with circulating monocytes (Low Wang, 2004).  
Endothelial dysfunction is associated with many pathological conditions, including 
hyperlipidemia, hypertension, metabolic syndrome, insulin resistance and diabetes. 
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Endothelial dysfunction is characterized by a loss of nitric oxide bioavailability mainly due 
to its inactivation under the effect of superoxide excessively produced and is considered a 
very important cellular event responsible for the adverse effects of high glucose on the 
blood vesels (Wadham et al, 2007, Brownlee, 2001). Both in vitro and in vivo studies show 
that exposure to hyperglycemia reduces endothelial NO availability and its bioactivity 
(Williams et al, 1998, Veves et al, 1998).  
The control of blood glucose homeostasis is mainly determined by two closely related 
physiological mechanisms: the capacity of the pancreas to secrete insulin and the biological 
action of this hormone on insulin-sensitive tissues, especially liver, muscle and adipose 
tissue (Foss-Freitas, 2004). It is well known that in type 2 diabetes mellitus and in metabolic 
syndrome, as well as in various other human pathological states such as glucose intolerance, 
obesity, polycystic ovary syndrome, essential hypertension, and, more recently, 
atherosclerosis, insulin resistance is either an associated condition or is considered to be a 
predictor or pathogenic factor (De Fronzo, 1988, 1991, Guizea, 2008). Insulin resistance is the 
condition in which normal amounts of insulin are inadequate to produce a normal 
physiologic response in the main target tissues of the pancreas hormone (fat, muscle, liver).  
Insulin resistance reduces the effects of insulin and results in elevated hydrolysis of 
triglycerides stored in the fat cells, leading to an increase of the free fatty acids’ level in 
plasma.  Insulin resistance in muscle cells reduces the glucose uptake, whereas in liver cells 
results in impaired glycogen synthesis and a failure to suppress glucose production. All 
these phenomena lead to reduced muscle glucose uptake and increased liver glucose 
production, thus contributing to the elevation of the blood glucose level, and accelerating 
the glucose toxicity associated with the insulin resistance (Freitas 2004, De Fronzo 1988, 
1991, Guizea 2008). 
The medical community agrees that the evaluation of the insulin resistance phenomena 
might be important for the assessment of hyperglycemia patients. According to literature 
data, the most efficient and scientifically correct methods for the evaluation of insulin 
resistance are “clamp” techniques. These procedures require i.v. access, multiple 
venipunctures, and take a long time, thus being relatively impractical for office assessment 
and difficult from the patients’ point of view. The euglycemic hyperinsulinemic clamp 
technique is the reference method, the “gold standard” for quantifying insulin sensitivity or 
resistance in vivo because it directly measures the effects of insulin on glucose use under 
steady state conditions (Freitas 2004). Besides the euglycemic hyperinsulinemic clamp 
technique, other clamp techniques have been developed: frequently sampled IV glucose 
tolerance test (FSIVGTT), insulin tolerance test (ITT), insulin sensitivity test (IST), and 
continuous infusion of glucose with model assessment (CIGMA). There are also some 
models available for the evaluation of insulin resistance depending on glucose and insulin 
levels in oral glucose tolerance tests: Insulin Sensitivity Index (ISI), Matsuda test, Caderholm 
test, Gut test, etc. Unfortunately, most of these methods share the disadvantages of the 
euglycemic hyperinsulinemic clamp, requiring i.v. access, multiple blood sampling, 
glucose/insulin infusion for several hours, being also difficult to use for the patients and for 
the specialists (McAuley 2001, Matsuda 2010).  
Largely because of the fact that the standard methods for assessing beta-cell function and 
insulin sensitivity, the hyperglycemic and euglycemic glucose clamps, are complex and 
costly to perform, several studies have been conducted to determine simpler and more 
applicable assessments (Dansuntornwong 2007).  
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So the mathematical models for the evaluation of insulin resistance depending on fasting 
levels of glucose and insulin are presently used. The most popular test of this kind is the 
Homeostatic model assessment (HOMA) of β-cell function and insulin resistance and it was 
first described in 1985 (Soonthornpun 2003). This test represents a method for assessing β-
cell function and IR from basal glucose and insulin or C peptide concentrations. The model 
has been widely used since it was first published. (Wallace 2004, Song 2007, Margina 2005). 
Recent data mentioned some other models for the evaluation of insulin resistance. 
Quantitative Insulin Sensitivity Check Index (QUICKI) can be evaluated depending on fasting 
levels of glucose and insulin. Many investigators believe that QUICKI is superior to HOMA as 
a way of determining insulin sensitivity (Katz 2000, Mather 2001, Yokoyama 2000).  
Since T2D, obesity, insulin resistance, metabolic syndrome, and atherosclerosis, the last one 
being the main complication of chronic hyperglycemia, share the inflammatory pattern, the 
aim of this research was to assess the profile of some markers of inflammation (hsCRP, IL6, 
E-selectin), of the adipocyte function (adiponectin) and of the endothelial status (plasma NO 
stable end products) in correlation with the insulin resistance indexes, in a Romanian group 
of patients.  
For this purpose 80 patients were selected and their informed consent was obtained. Any 
past or present insulin treatments, along with hematological, kidney or malignant diseases 
were exclusion criteria.  
2. Materials and methods 
2.1 Subjects and study design 
We included in our study 80 patients, 40 to 60 years old. Any past or present insulin 
treatment, along with any hematological or kidney diseases were an exclusion criterion. The 
protocol was approved by the local ethics committee and the informed consent of the 
patients was obtained. 
2.2 Biochemical evaluation 
For the studied patients we assessed, on à jeun blood samples, the following parameters: 
fasting plasma glucose (FPG), fasting plasma insulin, plasma lipids and lipoproteins (total 
cholesterol - TC, triglycerides –TG, low density lipoproteins - LDL, high density lipoproteins 
- HDL), plasma insulin level. Fasting plasma glucose and plasma lipids (TC, LDL, and HDL) 
were determined using automatic devices and commercial kits (Merck and Biorad), on an 
Olimpus 400 analyzer. Insulin, adiponectin, interleukin 6 and E-selectin were evaluated 
using ELISA kits (Invitrogen) on a ChemWell 1000 device. The NO stable end products 
(nitrite and nitrate) were evaluated using enzymatic catalysis coupled with Griess reaction 
(Gradinaru, 2003, Moshage, 1995, Archer, 2003) 
Using the values of fasting plasma glucose and insulin, several insulin sensitivity indexes 
have been evaluated (Quicki, HOMA-IR, 1/HOMA-IR, log(HOMA-IR), HOMA-B), 
according to the presented formula (McAuley 2001, Matsuda 2010, Dansuntornwong 2007, 
Wallace 2004). 
2.3 Statistical analysis 
Results are reported as means ± standard deviation (SD). Student t test was appropriately 
used for group comparisons. Correlations were assessed by a non-parametric test 
(Spearman). P values <0.05 were considered statistically significant. 
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3. Results an discussions 
The patients were divided into three groups, according to their BMI:  
 control group (n=20), BMI<25 kg/m2,  
 overweight group (n=30), 25 kg/m2≤BMI<30 kg/m2,  
 obese group (n=30), BMI≥30 kg/m2.  
Table 1 shows the general biochemical parameters for the three studied groups. 
Our results show that the weight increase is associated with a disturbance of the glycemic 
and lipid homeostasis. The fasting plasma glucose, total cholesterol and the lipoprotein 
levels increased from the control group to the other two studied groups. The LDL and TG 
increased significantly at the obese patients compared to controls, but not significantly at 
overweight patients compared to controls. All the other parameters varied significantly both 
in the overweight and the obese groups compared to the lean group. 
 
Evaluated parameters Control group Overweight group Obese group 
BMI (kg/m2) 21.46±2.02 27.28±1.61** 35.04±4.74** 
Fasting plasma glucose 
(mg/dL) 
85.8±7.25 128.2±74.17** 163.24±73.80** 
Total cholesterol (mg/dL) 176.60±34.46 201.05±38.48* 216.8±37.11** 
LDL cholesterol (mg/dL) 100.18±39.10 119.48±37.18 133.51±30.72* 
HDL cholesterol (mg/dL) 60.20±13.17 48.47±11.34* 48,80±15.52* 
Triglycerides (mg/dL) 81.10±55.67 86.75±52.61 173.36±129.21** 
*p<0.05, **p<0.01 
Table 1. The biochemical parameters for the overweight and obese patients compared to the 
control group 
Analyzing the lipid profile of the selected patients we pointed out that 36% of the 
overweight and 45.5% of the obese group were hypercholesterolemic (TC>220mg/dL). The 
HDL level did not meet the cardioprotective (>45mg/dL) level for 29% of the overweight 
and 54.5% of the obese patients.  
So, the analysis of the glucose and lipid markers only shows an increased risk of 
atherosclerotic events for some of the patients in the obese and overweight groups but does 
not allow identifying the mechanism involved in the potential endothelial lesions. 
Since the discovery of adiponectin, numerous studies have supported the theory that 
adiponectin has similar action with insulin and increases the pancreatic hormone’ metabolic 
function, as well as its anti-atherogenic properties; animal studies also suggest that 
adiponectin may exert a protective role in vascular homeostasis. In humans, plasma levels of 
adiponectin are negatively correlated with adiposity, and decreased plasma adiponectin 
levels are also observed in patients with diabetes, as well as in subjects with diseases caused 
by impairment of the endothelial function. Since adiponectin is secreted exclusively from 
adipose cells, deregulation of adiponectin synthesis and action may provide a link between 
obesity, insulin resistance, diabetes, vascular complications of diabetes and atherosclerosis 
(Arita et al, 1999, Hotta et al, 2000, Iwashima et al, 2004, Ouchi et al, 2000). So adiponectin, as 
well as the endothelial derived relaxing factor (NO), have anti-atherogenic properties. The 
imbalance of these two markers caused by the weight increase is associated with a general 
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impairment of the vascular function and with a loss of the glycemic, lipid and lipoproteic 
control.  
Statistical analysis of the recorded data revealed that the adiponectin level was significantly 
lower at overweight (p=0.001) and obese patients (p=0.001) compared to controls (fig 1).  
 
 
 
 
Fig. 1. Dynamics of adiponectin in correlation with the BMI of the studied patients 
The nitrite level also decreased inversely correlated with the body mass index of the 
patients. Our data showing that the synthesis of NO at the endothelial level decreases from 
lean subjects to the overweight and obese ones might be also explained by the results of 
Chen et all (2003), which proved that adiponectin stimulates the NO production at the 
endothelial level (fig 2). 
 
 
 
 
Fig. 2. The NO stable end products level in correlation with the BMI of the studied patients 
For all the patients included in the study our results showed a significant, positive 
correlation between the adiponectin level and the NO stable end products (fig 3). This type 
of correlation also supports the theory that there is a regulatory mechanism between 
adiponectin and NO synthesis.  
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Fig. 3. The correlation between the NO stable end products and the plasma adiponectin level 
for the study group 
The IL6 and hsCRP levels increased significantly at overweight and obese patients, in 
correlation with the BMI (fig 4). The increase was significant for the obese patients, in the 
case of both parameters and not significant for both parameters in overweight patients, 
compared to controls.  
 
 
Fig. 4. IL6 and hsCRP levels for the studied groups 
The E-selectin level was similar in the overweight and obese groups but was significantly 
higher (p<0.001) compared to lean controls (fig 5). According to literature data, adhesion 
molecules of the selectin family are poorly expressed by the resting endothelium and are 
upregulated during atherogenesis, acute infections and granulomatous diseases. Thus, 
endothelial adhesion molecules are a result of both acute responses against pathogens and 
chronic inflammatory processes, such as those leading to progressive formation of 
atherosclerotic plaques (Ferri, 1998, Monaco, 2009). The elevated plasma levels of soluble 
endothelial adhesins might constitute indexes of increased adhesion molecule expression by 
the intact vascular endothelium in vivo. The results showing high levels of E-selectin in 
overweight and obese patients suggest that an early endothelial activation might be present 
in correlation with the weight increase, favoring the development of overt vascular lesions. 
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So, the vascular endothelium from obese patients releases endothelium-derived substances 
that can constitute markers of endothelial damage, such as E-selectin.  
 
 
Fig. 5. E-selectin dynamics for the studied groups 
The term “insulin resistance” as it is used in clinical and experimental settings refers to the 
inability of insulin to promote the normal homeostasis of glucose. That means that the 
reduced insulin action demands the presence of higher-than-normal concentrations of 
insulin in order to maintain a normal utilization of glucose by insulin target tissues. Thus, 
the term “insulin resistance” implies the existence of metabolic insulin resistance, which 
reflects an inadequate effect of insulin on glucose metabolism, but does not address other 
aspects of insulin action (Low Wang, 2004). Many investigators have studied simple 
surrogate indices of insulin resistance in comparison with the index assessed by euglycemic-
hyperinsulinemic clamp. It has been established that homeostasis model assessment of 
insulin resistance HOMA-IR is a useful index of insulin resistance in diabetic and 
nondiabetic subjects and that its logarithmic transformation or its reciprocal value might 
make it more accurate (Mather et al, 2001, Yokoyama et al, 2003).  
The HOMA model allows the evaluation of an insulin resistance index (HOMA-IR) and also 
of an index for the β-cell function (HOMA-B). These two parameters estimate the deficiency 
of the pancreatic β-cells based on a mathematical model that takes into account the 
interrelation (by negative feed-back) between glucose and insulin under normal metabolic 
control. This interrelation involves both the secretion of the pancreatic hormone and the 
hypoglycemic insulin action on target tissues. According to this model, the relationship 
between glucose and insulin, in the basal state, reflects the balance between hepatic glucose 
output and insulin secretion, which is maintained by a feedback loop between the liver and 
β-cells (Wallace, 2004, Rutter, 2008). Quicki is also defined as a result of the in vivo 
interaction between glucose and insulin in fasting conditions and, according to some 
investigators, reflects even better than HOMA, the variations of the insulin sensitivity of 
target tissues.  
The literature data does not define reference values for HOMA and for Quicki parameters; 
clinical studies show that Quicki and 1/HOMA-IR are significantly lower in obese people 
compared to healthy subjects (Mather et al, 2001, Yokoyama et al, 2003). For the studied 
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patients we evaluated HOMA-IR and HOMA-B, the reciprocal value of HOMA-IR and 
Quicki (fig 6 and 7). 
 
 
Fig. 6. The insulin as well as HOMA-IR and Quicki parameters for the studied groups 
 
 
Fig. 7. The HOMA-B parameter for the three study groups 
The increase of the insulin level is significant for the obese patients compared to controls. 
HOMA-IR and Quicki varied significantly in both overweight and obese subjects compared 
to controls. The insulin level and the insulin resistance index HOMA-IR increase from the 
control group to the overweight and significantly to the obese patients. So, in obese patients 
a significantly higher amount of insulin is necessary in order to maintain the normal fasting 
plasma glucose level; the weight increase might prevent the insulin, even if it’s secreted in 
higher quantity, from exerting its action at the target tissues’ level. 
In table 2 we present the values obtained for the reciprocal values and the logarithmic 
values of HOMA-IR, respectively.  
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Evaluated parameters Control group Overweight group Obese group 
Insulin (μUI/mL) 5.73±1.23 5.93±1.65 8.17±4.51** 
1/HOMA-IR 0.86±0.17 0.68±0.28* 0.50±0.34** 
Log(HOMA-IR) 0.103±0.07 0.24±0.22* 0.46±0.33** 
Table 2. The values for 1/HOMA-IR and log (HOMA-IR) for the studied patients 
The test used for the evaluation of the insulin resistance/sensitivity phenomena are 
significantly different both for overweight and obese patients compared to controls. Only 
the fasting level of insulin does not indicate the degree of insulin resistance. So, the 
calculated parameters show more precisely than the insulin evaluation the risk of secondary 
health issues associated with the body mass increase. These changes are revealed starting 
from the overweight stage and not from the obese stage, as it is the case with insulin.  
All the indexes used for the evaluation of insulin resistance/β-cell function are significantly 
different for both overweight and obese patients compared to controls.  
For the studied patients, the decrease of the adiponectin level was correlated with an 
increase of HOMA-IR. The IL6 and hsCRP levels increased significantly in correlation with 
HOMA-IR (fig 8). 
 
 
Fig. 8. Correlation of the IL6 level with HOMA-IR 
IL6 production is increased in human obesity and the increase is correlated with an increase 
of the insulin resistance. IL6 can serve as a direct link between adipose tissue and insulin 
resistance. 
The American Diabetes Association defines pre-diabetes by levels of fasting plasma glucose 
(FPG) between 100 and 125 mg/dL. Analyzing the dynamics of insulin resistance 
parameters in the group of selected patients in correlation with the fasting plasma glucose 
level, we obtained the values presented in table 3.  
The analysis of the data depending both on the BMI and the fasting plasma glucose, shows 
that all of the parameters defined for the evaluation of insulin resistance and beta cell 
function increase significantly in the groups with FPG>125mg/dL, independently of their 
BMI. The control group and the overweight and obese groups with FPG<100mg/dL had 
similar values of the evaluated parameters (fig 9). 
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Evaluated parameters
Overweight group Obese group 
FPG<100mg/dL FPG>125mg/dL FPG<100mg/dL FPG>125mg/dL 
Insulin (μUI/mL) 5.68±0.81 6.72±2.79 5.53±1.30 10.22±5.29 
HOMA-IR 1.22±0.21 3.55±1.63 1.26±0.35 5.58±2.78 
1/HOMA-IR 0.85±0.17 0.35±0.18 0.84±0.20 0.22±0.10 
Log(HOMA-IR) 0.11±0.05 0.51±0.22 0.12±0.09 0.70±0.21 
HOMA-B 96.64±36.39 19.99±13.17 70.51±19.01 25.04±17.92 
Quicki 2.42±0.57 1.24±0.36 2.41±0.65 0.99±0.20 
Table 3. Parameters for the evaluation of beta cell function and insulin resistance in 
correlation with the fasting plasma glucose level 
 
 
Fig. 9. Parameters for the evaluation of insulin resistance/sensitivity for the control group 
The groups with FPG>125mg/dL, either overweight or obese showed significant increases 
of the parameters for the evaluation of insulin resistance or beta cell function compared to 
the control group. 
The same kind of dynamics was obtained for the IL6 levels, which increased in both 
overweight and obese groups with FPG>125mg/dL, compared to the FPG<110mg/dl 
corresponding sub-groups (fig 10). The differences were significant only for the obese 
subgroups, and not-significant for the overweight ones, compared to controls.  
 
 
Fig. 10. Interlukin 6 dynamics in the subgroups of patients, defined both according to their 
BMI and their fasting plasma glucose level 
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No significant differences were recorded between the sub-groups, regarding the E-selectin 
levels (fig 11).  
 
 
Fig. 11. E-selectin level for the sub-groups of patients, defined according both to their BMI 
and FPG  
4. Conclusions 
Our data revealed an impairment of the endothelial function expressed by both the decrease 
of the NO stable end products’ and the adiponectin level, in the overweight and obese 
groups. These results are in agreement with data from Chen et all (2003), which proved that 
adiponectin stimulates the NO production at the endothelial level. The synthesis of IL6 as 
well as the hsCRP plasma level was highly correlated with the body mass index, suggesting 
the involvement of inflammatory phenomena in the development of endothelial dysfunction 
associated with the weight gain and the insulin resistance. So, the evaluation of adiponectin 
as well as of the NOS activity might prove to be useful predictive markers of atherogenic 
disorders at overweight and obese patients. Interleukin 6 is one of the molecules that 
contribute to the amplifying of the inflammatory signal in patients with dismetabolic 
syndrome, taking part into the relationship between the adipose tissue, the liver and the 
endothelium.  
The current study demonstrates elevated plasma soluble adhesion molecule levels in weight 
increase patients with increased insulin resistance indexes, in spite of the absence of overt 
vascular damage. On the other hand, the increase of the E-selectin level, associated with the 
decrease synthesis of NO shows an activation of the endothelium, associated with the 
insulin resistance. We hypothesized that the early endothelial activation precedes the onset 
of overt vascular damage in obese patients and might be responsible for the increased 
release of E-selectin into the bloodstream. 
Since insulin resistance is frequently associated as predictor or pathogenic factor in different 
pathological conditions (type 2 diabetes mellitus, obesity, glucose intolerance, essential 
hypertension, polycystic ovary syndrome), it is important to have simple, accessible tools for 
the evaluation of insulin sensitivity of target tissues to the insulin action in humans. The 
euglycemic hyperinsulinemic clamp technique remains the reference method for 
quantifying the sensitivity to insulin action but it cannot be applied on a large scale or in the 
context of routine investigations. For this reason, alternative methods have been developed, 
including the HOMA model and the Quicki test.  
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Our results show that the above mentioned parameters vary significantly in correlation with 
both weight and glucose level in a group of Romanian subjects.  
The parameters for the evaluation of insulin resistance and beta cell function might be used 
in clinical studies in correlation with the level of fasting plasma glucose and not simply as 
indicators of the degree of insulin resistance in overweight and obese patients.  
Since inflammation is an important feature of hyperglycemia and insulin resistance, future 
therapy for these pathological conditions should focus not only on the reduction of the 
plasma glucose and/or the glycated hemoglobin levels but also on the decrease of the 
inflammatory markers, in order to protect the endothelium and to reduce the associated 
cardio-vascular risk.    
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